RecruitingPrimary Sclerosing CholangitisLiver Transplant, ComplicationsPSC
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
Eligible age
18–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with
Sponsor: Mayo Clinic
You may qualify if…
- ✓ Adults aged 18-75 irrespective of gender who have undergone LT for PSC or PSC-related liver malignancy between 1 year and 7 years (inclusive) prior to study enrollment
- ✓ Absence of rPSC at time of study enrollment
- ✓ At least one of the following additional features that increase risk of rPSC
- ✓ LT performed for cholangiocarcinoma
- ✓ Concurrent inflammatory bowel disease
- ✓ Any episode of cytomegalovirus viremia in the post-transplant period before study enrollment
- ✓ Any episode of acute cellular rejection in the post-transplant period before the study enrollment
- ✓ If target enrollment of 40 patients is not achieved during the first 6 months of study, we will remove f(iii) inclusion criteria to expand enrollment to any patient meeting the other inclusion/exclusion criteria.
You may not qualify if…
- ✕ Presence of ischemic cholangiopathy which can mimic rPSC
- ✕ LT performed for primary biliary cholangitis or autoimmune hepatitis, or PSC with overlapping primary biliary cholangitis or autoimmune hepatitis, which may recur after LT and confound assessment of cholestasis
- ✕ Unaddressed post-LT hepatic artery compromise (e.g thrombosis, stenosis) which can mimic rPSC
- ✕ History of total colectomy for curative treatment of ulcerative colitis which reduces risk of rPSC
- ✕ Baseline GFR \<30 ml/min which precludes administration of fenofibrate
- ✕ Previously known intolerance or allergy to fenofibrate
- ✕ Other clinically significant comorbid condition, including inability to provide consent and psychiatric conditions, which in the opinion of the study team, may interfere with patient treatment, safety, assessment, or compliance with the treatment
- ✕ Female participants that are pregnant or planning to become pregnant
Where it's recruiting
Arizona
Scottsdale
Source: ClinicalTrials.gov · NCT06905054 · last updated 2025-06-27